ANRO
Alto Neuroscience, Inc.
NYSE: ANRO · HEALTHCARE · BIOTECHNOLOGY
$25.80
+6.15% today
Updated 2026-04-30
Market cap
$859.49M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.19
Dividend yield
—
52W range
$2 – $28
Volume
0.3M
Alto Neuroscience, Inc. (ANRO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $210000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -100.0% | — | — | — |
| Cost of revenue | $145000.00 | $342000.00 | $373000.00 | $502000.00 | $661000.00 |
| Gross profit | $65000.00 | $-342000.00 | $-373000.00 | $-502000.00 | $-661000.00 |
| Gross margin | 31.0% | — | — | — | — |
| R&D | $8.37M | $23.69M | $30.29M | $47.00M | $45.62M |
| SG&A | $3.90M | $5.50M | $7.52M | $21.61M | $20.75M |
| Operating income | $-12.06M | $-29.19M | $-37.81M | $-68.61M | $-66.36M |
| Operating margin | -5741.0% | — | — | — | — |
| EBITDA | $-9.04M | $-27.37M | $-34.56M | $-68.61M | $-65.70M |
| EBITDA margin | -4305.7% | — | — | — | — |
| EBIT | $-9.19M | $-27.71M | $-34.94M | $-62.81M | $-66.36M |
| Interest expense | — | $0.00 | $1.37M | $1.38M | $2.47M |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-9.19M | $-27.71M | $-36.30M | $-61.43M | $-63.24M |
| Net income growth (YoY) | — | -201.6% | -31.0% | -69.2% | -2.9% |
| Profit margin | -4374.8% | — | — | — | — |